PE20142448A1 - Compuestos de n-alquiltriazol como antagonistas de lpar - Google Patents

Compuestos de n-alquiltriazol como antagonistas de lpar

Info

Publication number
PE20142448A1
PE20142448A1 PE2014002232A PE2014002232A PE20142448A1 PE 20142448 A1 PE20142448 A1 PE 20142448A1 PE 2014002232 A PE2014002232 A PE 2014002232A PE 2014002232 A PE2014002232 A PE 2014002232A PE 20142448 A1 PE20142448 A1 PE 20142448A1
Authority
PE
Peru
Prior art keywords
compounds
alkyltriazole
lpar
antagonists
triazol
Prior art date
Application number
PE2014002232A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142448(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20142448A1 publication Critical patent/PE20142448A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PE2014002232A 2012-06-20 2013-06-17 Compuestos de n-alquiltriazol como antagonistas de lpar PE20142448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
PE20142448A1 true PE20142448A1 (es) 2015-01-28

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002232A PE20142448A1 (es) 2012-06-20 2013-06-17 Compuestos de n-alquiltriazol como antagonistas de lpar

Country Status (22)

Country Link
US (1) US9321738B2 (instruction)
EP (1) EP2864300A1 (instruction)
JP (1) JP2015520202A (instruction)
KR (1) KR20150021057A (instruction)
CN (1) CN104411692A (instruction)
AU (1) AU2013279512A1 (instruction)
BR (1) BR112014030685A2 (instruction)
CA (1) CA2869541A1 (instruction)
CL (1) CL2014003243A1 (instruction)
CO (1) CO7131358A2 (instruction)
CR (1) CR20140525A (instruction)
EA (1) EA201492285A1 (instruction)
HK (1) HK1206342A1 (instruction)
IL (1) IL236088A0 (instruction)
IN (1) IN2014DN09348A (instruction)
MA (1) MA37764A1 (instruction)
MX (1) MX2014014710A (instruction)
PE (1) PE20142448A1 (instruction)
PH (1) PH12014502789A1 (instruction)
SG (1) SG11201407220YA (instruction)
UA (1) UA109868C2 (instruction)
WO (1) WO2013189864A1 (instruction)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists
CA2869564A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
EA033923B1 (ru) 2013-03-15 2019-12-10 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
ES2824801T3 (es) 2014-06-27 2021-05-13 Ube Industries Sal de compuesto heterocíclico sustituido con halógeno
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
CN112041316B (zh) * 2017-12-19 2024-11-22 百时美施贵宝公司 作为lpa拮抗剂的异噁唑o-连接的氨基甲酰基环己基酸
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
SG11202005703TA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Cyclohexyl acid triazole azoles as lpa antagonists
JP7208240B2 (ja) * 2017-12-19 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン
EP3728196B1 (en) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3728209A1 (en) * 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
ES2944304T3 (es) * 2017-12-19 2023-06-20 Bristol Myers Squibb Co Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
KR102726939B1 (ko) 2017-12-19 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
TWI830713B (zh) * 2017-12-19 2024-02-01 美商必治妥美雅史谷比公司 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸
CN117126152A (zh) * 2017-12-29 2023-11-28 生物马林药物股份有限公司 用于疾病治疗的乙醇酸氧化酶抑制剂
EP3853232B1 (en) 2018-09-18 2023-03-01 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
KR102800284B1 (ko) * 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
CN114728168B (zh) * 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
CN117295724A (zh) * 2021-05-13 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
JP2014508111A (ja) * 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
AU2013279512A1 (en) 2014-10-16
EA201492285A1 (ru) 2015-04-30
CR20140525A (es) 2015-01-12
IL236088A0 (en) 2015-02-01
PH12014502789A1 (en) 2015-02-09
CO7131358A2 (es) 2014-12-01
WO2013189864A1 (en) 2013-12-27
US20150133511A1 (en) 2015-05-14
JP2015520202A (ja) 2015-07-16
KR20150021057A (ko) 2015-02-27
MA37764A1 (fr) 2016-01-29
CA2869541A1 (en) 2013-12-27
US9321738B2 (en) 2016-04-26
EP2864300A1 (en) 2015-04-29
SG11201407220YA (en) 2014-12-30
BR112014030685A2 (pt) 2017-06-27
CN104411692A (zh) 2015-03-11
IN2014DN09348A (instruction) 2015-07-17
HK1206342A1 (en) 2016-01-08
UA109868C2 (ru) 2015-10-12
CL2014003243A1 (es) 2015-03-20
MX2014014710A (es) 2015-03-04

Similar Documents

Publication Publication Date Title
PE20142448A1 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
PE20142305A1 (es) Compuestos de n-ariltriazol como antagonistas de lpar
PE20190211A1 (es) Acidos de carbamoiloximetil triazol ciclohexilo como antagonistas de acido lisofosfatidico (lpa)
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
CL2011003072A1 (es) Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras.
CL2012001221A1 (es) Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
MX354102B (es) Derivados de bencimidazol-prolina.
CR20140038A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alquiniloxi-etil}-1h-[1,2,4]triazol sustituidos
CU20160007A7 (es) Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
PE20141607A1 (es) Compuestos heterociclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparacion
UA109867C2 (ru) Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
CL2018000057A1 (es) Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares
PE20160846A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
EA201600435A1 (ru) Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
MX378947B (es) Composición farmacéutica estable para administración oral.
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона

Legal Events

Date Code Title Description
FD Application declared void or lapsed